Protagonist Therapeutics Inc diskutieren
Protagonist Therapeutics Inc
WKN: A2AP32 / Symbol: PTGX / Name: Protagonist / Aktie / Micro Cap /
138,00 €
1,48 %
Protagonist Therapeutics (PTGX) was upgraded by Wolfe Research to "strong-buy".
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by TD Cowen.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its "outperform" rating reaffirmed by Citigroup Inc..
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $130.00 to $175.00. They now have a "buy" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its "outperform" rating reaffirmed by Wedbush.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) was given a new $170.00 price target by Truist Financial Corporation. They now have a "buy" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its price target raised by BMO Capital Markets from $112.00 to $178.00. They now have an "outperform" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Neueste Beiträge
TD_Securities in Talon Metals Corp. diskutieren